---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-051106"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:44:07.619713+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agios Q4 net loss $98.6M; FDA approved PYRUKYND for PK deficiency; cash $1.3B

## Summary
- Net loss $98.6M in Q4 2021 vs $84.5M in Q4 2020; full-year net loss $356.5M.
- Received FDA approval for PYRUKYND (mitapivat), first therapy for hemolytic anemia in adults with PK deficiency.
- Cash, cash equivalents and marketable securities $1.3B as of Dec. 31, 2021; expects to fund operations to cash-flow positivity.
- Dosed first patients in three pivotal trials of PYRUKYND in thalassemia and sickle cell disease.
- R&D expenses $73.3M in Q4 2021, up from $59.4M in Q4 2020 due to pivotal study start-up costs.

## SEC filing metadata
- accession: 0001193125-22-051106
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312522051106/0001193125-22-051106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312522051106/d252010d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-051106
- JSON: https://secwatch.observer/filing/0001193125-22-051106.json
- Plain text: https://secwatch.observer/filing/0001193125-22-051106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.